Cerenome vs Neuroone Medical Technologies
CNSY and NMTC side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNSY and NMTC compare
Neuroone Medical Technologies is the larger company, worth 1.3 times as much as Cerenome ($6.4M against $4.8M).
Neuroone Medical Technologies grew revenue faster over the last twelve months (42.8% versus −21.0% for Cerenome).
Neuroone Medical Technologies keeps more of each dollar of sales as profit, with a net margin of −78.6% compared with −621% at Cerenome.
Neuroone Medical Technologies scores higher on the StockData Score (11 against 8 for Cerenome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNSY | NMTC |
|---|---|---|
| Size and price | ||
| Market cap | $4.8M | $6.4M |
| Share price | $0.630 | $0.707 |
| Change, 1 year | −95.1% | −82.9% |
| Change, 5 years | −98.3% | −94.8% |
| Beta (5Y) | 4.92 | 0.40 |
| Employees | 28 | 18 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 3 | 3 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× | 0.7× (better) |
| P/B | 0.9× (better) | 1.7× |
| FCF yield | −492% | −111% (better) |
| Fair value | $2.14 | $3.52 |
| Margin of safety | 70.5% | 80.0% (better) |
| Growth | ||
| Revenue growth (TTM) | −21.0% | 42.8% (better) |
| Profitability | ||
| Gross margin | – | 55.6% |
| Operating margin | −628% | −83.4% (better) |
| Net margin | −621% | −78.6% (better) |
| FCF margin | −560% | −75.6% (better) |
| Return on equity | −614% | −125% (better) |
| Return on invested capital | – | −672% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −1200.0× | – |
| Current ratio | 1.37 | 2.84 (better) |
| Altman Z-score | −58.37 | −19.47 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 8.3% | 22.7% |
| Held by insiders | 4.2% | 85.4% |
| Insider net buying, 12 months | $0 | $682K (better) |
| Short interest, % of float | 11.6% | 15.6% |
Go deeper
- CNSY stock overview
- CNSY income statement
- CNSY valuation and score
- NMTC stock overview
- NMTC income statement
- NMTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.